Antidepressant sexual dysfunction (and other psych meds that cause it)

Which drugs cause sexual side effects

SSRIs and SNRIs are the classic offenders. Rates in trials underestimate real-world rates because early trials used non-specific questions ("any sexual side effects?") that patients often did not endorse. Studies using specific questionnaires (Arizona Sexual Experience Scale, Changes in Sexual Functioning Questionnaire) find 40 to 70 percent rates for most SSRIs. Ranking from higher to lower rates: paroxetine, citalopram, sertraline, escitalopram, fluoxetine. SNRIs (venlafaxine, duloxetine, desvenlafaxine, levomilnacipran) show similar rates to SSRIs.

TCAs cause sexual side effects at similar rates to SSRIs, primarily via anticholinergic and antihistaminergic effects.

MAOIs (phenelzine, tranylcypromine) cause substantial sexual side effects.

Antipsychotics that raise prolactin (risperidone, paliperidone, haloperidol, and to a lesser extent olanzapine) cause hyperprolactinemia which suppresses gonadotropin release and reduces sex hormones. This produces libido loss, erectile dysfunction, and menstrual irregularities. Aripiprazole, brexpiprazole, and cariprazine (partial agonists) do not raise prolactin.

Antidepressants with the lowest sexual side effect rates: bupropion (dopamine and norepinephrine reuptake inhibitor, may actually improve sexual function), mirtazapine (5-HT2A/2C antagonism seems to preserve sexual function), vortioxetine (multimodal serotonergic drug with lower rates than SSRIs in trials), vilazodone (SSRI plus 5-HT1A partial agonist), trazodone (though it can cause priapism in some men). See our bupropion vs sertraline comparison for the sexual-side-effect discussion in that specific pairing.

Non-antidepressant psychiatric drugs: lithium (dose-related sexual dysfunction), benzodiazepines (dose-related, often overlooked), some anticonvulsants.

Presentations by mechanism

Understanding the mechanism helps predict which intervention will work.

Serotonergic sexual dysfunction (SSRIs, SNRIs): 5-HT2A activation reduces nitric oxide signaling, decreases dopamine release, and dampens sexual response. Presents with delayed orgasm, anorgasmia (women and men), decreased genital sensation, decreased libido. Erectile dysfunction is common but usually incomplete.

Prolactin-mediated sexual dysfunction (risperidone, paliperidone, haloperidol): Elevated prolactin suppresses hypothalamic-pituitary-gonadal axis, reducing testosterone and estrogen. Presents with libido loss, erectile dysfunction, amenorrhea, galactorrhea, gynecomastia. Prolactin level confirmation is useful.

Anticholinergic sexual dysfunction (TCAs, benztropine, first-gen antipsychotics): Decreased genital secretions, ED via reduced parasympathetic input. Presents with vaginal dryness, ED, delayed orgasm.

Alpha-1 antagonism (prazosin, trazodone, some antipsychotics): ED and priapism (medical emergency, particularly with trazodone).

Management

Multiple strategies exist. Choice depends on drug, severity, treatment success on the causative drug, and patient preference.

Wait and see: 10 to 20 percent of SSRI sexual side effects resolve on their own within 6 months. Watchful waiting is reasonable if the depression response is good and side effects are mild.

Dose reduction: Sexual side effects are dose-related for most drugs. Lowest effective dose may reduce them.

Drug holiday: For drugs with short half-life (sertraline, paroxetine, venlafaxine, duloxetine), skipping the dose Friday and Saturday to allow weekend sexual activity has been described (Rothschild, Am J Psychiatry). Does not work for fluoxetine (long half-life) or drugs with steady-state effects. Not recommended for patients at risk of discontinuation symptoms.

Augmentation with bupropion: 150 mg once or twice daily added to SSRI is the most-supported augmentation. Effect size is modest but real.

PDE5 inhibitors (sildenafil, tadalafil, vardenafil): First-line for SSRI-induced erectile dysfunction in men. Less studied but sometimes tried in women.

Switch to a lower-rate drug: Bupropion, mirtazapine, vortioxetine, vilazodone, or trazodone are the standard switch targets. Effect is usually clear within 4 to 8 weeks.

Cyproheptadine, buspirone, ginkgo biloba have all been tried with mixed evidence.

For antipsychotic-induced prolactin sexual dysfunction: switch to a partial agonist (aripiprazole, brexpiprazole, cariprazine) or add adjunctive aripiprazole to reduce prolactin.

Post-SSRI sexual dysfunction (PSSD)

PSSD is a syndrome where sexual dysfunction that started during SSRI treatment persists after the drug is stopped, sometimes for months or years. It is real, uncommon, and poorly understood.

How common: Not well established. Case series and patient-report registries suggest hundreds to low thousands of cases have been documented globally, but the denominator (how many people take SSRIs) is enormous, so the actual rate is likely well under 1 percent. Some sources cite higher estimates; the honest answer is that the epidemiology is not settled.

What it looks like: Persistent genital anesthesia, anorgasmia, decreased libido, and sometimes emotional blunting after SSRI discontinuation. Symptoms can persist for months to years. Regulatory bodies (EMA, Health Canada, Australia's TGA) have added PSSD warnings to SSRI labels. FDA has not.

Mechanism: Unknown. Hypotheses include long-term epigenetic changes to serotonin receptors, dysregulation of nitric oxide signaling, or persistent hormonal changes.

Treatment: No consistently effective treatment. Anecdotal reports of benefit from bupropion, low-dose aripiprazole, PDE5 inhibitors, or vortioxetine. No RCTs.

Discussion with patients: PSSD should be part of informed consent for SSRI initiation, particularly in younger patients or those with strong sexual health priorities. The specific risk is low but not zero. The antidepressants and sexual side effects guide covers this in detail.

Common questions

Do sexual side effects go away after stopping the medication? Usually yes, within 1 to 4 weeks for most people. A small subset (probably well under 1 percent) develops post-SSRI sexual dysfunction (PSSD) which can persist for months to years. Recognition of PSSD is important; risk is real but low.

Which SSRI has the lowest sexual side effects? Among SSRIs specifically, fluoxetine may have slightly lower rates than paroxetine. Among all antidepressants, bupropion has the lowest rates and is often used specifically for this reason. Mirtazapine, vortioxetine, and vilazodone are also lower than standard SSRIs. See our bupropion vs sertraline comparison.

Can I take Viagra with an SSRI? Yes. Sildenafil and other PDE5 inhibitors are first-line for SSRI-induced erectile dysfunction in men. No interaction with SSRIs beyond standard cardiovascular considerations. Discuss with a prescriber before starting, particularly if there is any cardiovascular history.

Does bupropion actually help SSRI sexual side effects? Yes, modest but real effect size in trials. Adding bupropion 150 to 300 mg per day to an SSRI reduces sexual side effects in a subset of patients. Not universally effective but the most-supported augmentation strategy.

Do antipsychotics cause sexual side effects? Yes, particularly prolactin-raising ones (risperidone, paliperidone, haloperidol). Switching to aripiprazole, brexpiprazole, or cariprazine typically resolves prolactin-mediated sexual dysfunction. See the atypical antipsychotics class page for the full profile.

How do I bring this up with my prescriber? Directly. Sexual side effects are one of the most common reasons people stop psychiatric medications, and prescribers know this. If the medication is helping the depression or anxiety but the sexual side effects are a problem, there are real options (dose adjustment, augmentation, switch). Not bringing it up often leads to silent non-adherence.

Is this a permanent problem? Usually not. For most patients, sexual function returns within 1 to 4 weeks of stopping the causative drug. PSSD is a distinct minority. Do not assume the drug caused permanent damage until it has been off for at least 8 weeks.

Sources

• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266.
• Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126(2):91-99.
• Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514-1516.
• Reisman Y. Post-SSRI sexual dysfunction. BMJ. 2020;368:m754.
• Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125-134.
• European Medicines Agency. PSSD label update, June 2019 (EMA/PRAC/265216/2019).